Secular trends in medical knowledge generation, information dissemination, and shared medical decision making will substantially alter the structure of industry-sponsored clinical research—all for the better. These trends include democratization of medical information and movement away from a paternalistic health care model. Both challenge legacy behaviors in industry research (where clinical data are typically sequestered and intended solely for internal company, regulatory body, and medical publication uses) and in product marketing to physician providers and patient consumers. The thriving interest in open science and the inevitable widespread adoption of data sharing will be the centerpieces of this positive disruption (1). Concerns of specious multiplicity of secondary data analyses, groundless litigation (2), exposure of confidential information for industry (3), and the desire for proprietary access to data in academia (3, 4) hinder the potential to improve public health and augment patient safety by sharing and pooling data sets resident in medical industry, academia, and regulatory authorities (5), including neutral and negative studies that go unpublished.
Link to access full article: annals.org/article.aspx?doi=10.7326/0003-4819-158-12-201306180-00011